Novo Nordisk's Q3 results exceeded expectations, driven by a 53% increase in pill sales and strong net patient growth, dispelling fears of oral product cannibalization. The company is also reducing capital expenditures and expanding free cash flow, supported by the integration of Catalent, which strengthens its competitive position against Eli Lilly. Despite risks from Eli Lilly's advanced drug pipeline and manufacturing, Novo Nordisk's current valuation offers significant downside protection. This positive outlook supports a buy rating with a target price of $57.24, implying about 34% upside from the current price of $42.62.
Novo Nordisk shares are trading at USD 40.40 on Pluang as of Nov 09, 2026 15:11 WIB, showing a modest gain of 0.22% for the day. The stock's market capitalization stands at $178.46 billion, reflecting its significant presence in the health sector. Investors on Pluang typically hold this stock for about 119 days, indicating steady interest despite recent earnings news.
Novo Nordisk A/S has been upgraded to a Strong Buy rating following robust third-quarter results and accelerating adoption of its Wegovy pill. The stock trades at a low valuation compared to pharma peers, supporting a value-driven investment case. An...
Novo Nordisk's stock rose 6.32% after Q3 results showed the Wegovy oral pill took about 80% of new obesity drug prescriptions in the US, surpassing expectations despite price cuts and competition. The pill's rapid adoption is driving volume growth, o...
Novo Nordisk reported strong Q3 results with revenue growth driven by its obesity care, especially the Wegovy pill, offsetting declines in diabetes products. International markets outperformed the U.S., and the company achieved a 40.1% adjusted opera...
